Fayetteville, AR (PRWEB) October 20, 2022 The University of California San Francisco (UCSF) Health Hub has selected CardioWise, Inc. as a Digital Health
CardioWise™ Receives US FDA 510(k) Clearance for Stretch Quantifier for Endocardial Engraved Zones (SQuEEZ) Heart Function Analysis Software
Share Article
CardioWise, Inc., is pleased to announce Clearance of its 510(k) application by the US Food and Drug Administration (FDA) for its heart function analysis software, Stretch Quantifier for Endocardial Engraved Zones (SQuEEZ). CardioWise can now market the SQuEEZ analysis to provide give caregivers an easy-to-read, quantitative 4D color model that allows physicians to make better, more informed decisions about their patients’ care.” -Jack Coats, CEO of CardioWise, Inc. FAYETTEVILLE, Ark. (PRWEB) January 06, 2021 The 510(k) premarket notification letter indicates that the FDA has determined that SQuEEZ may be legally marketed in interstate commerce according to its indications for use. SQuEEZ is an image analysis software application for cardiac Computer T